Ensartinib is a new oral, second-generation small-molecule drug, which is a strong and highly selective ALK-tyrosine kinase inhibitor (TKI).[10,11] Herein, we present 2 cases of patients with IMT receiving ensartinib as targeted treatment who obtained clinical benefits. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.